Specific delivery of anti-fibrotic therapy to a diseased kidney.

What is it about?

New method to deliver anti-fibrotic therapy (anti-TGF-B anti-body) to diseased kidneys while limiting its exposure to other tissues (potentially reducing unwanted side effects). A specific component of fibrosis, FnEDA protein, was used to "anchor" the anti-body to the diseased kidney. This approach improved inflammation and fibrosis in the kidney.

Featured Image